<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02544854</url>
  </required_header>
  <id_info>
    <org_study_id>15-068</org_study_id>
    <nct_id>NCT02544854</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic/Pharmacodynamic Model of Propofol in Children</brief_title>
  <official_title>Pharmacokinetic/Pharmacodynamic Model of Propofol in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pontificia Universidad Catolica de Chile</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pontificia Universidad Catolica de Chile</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      By measuring plasmatic concentration of propofol at different intervals during surgery of
      children aged 1 to 12 years old and measuring Bispectral Index (BIS) as a surrogate for
      cerebral activity, the investigators aim to create a pharmacokinetic/pharmacodynamic model of
      propofol for children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Propofol is an intravenous anesthetic capable of providing a safe general anesthesia, free
      from many of the adverse effects associated with inhalation anesthetics (postoperative nausea
      and vomiting, agitation on awakening, seizures and trigger malignant hyperthermia crisis) and
      widely used in adults, but even less so in children. This is due to the fact that its
      pharmacological characteristics have not been clarified at all in the pediatric population.

      The physiological maturation of different systems in children, as well as changes in body
      composition and metabolism may determine significant changes in the pharmacokinetics
      (distribution volumes and clearance) of children. Moreover, within the same age group,
      variations across different individuals may make even less predictable the pharmacokinetic
      models currently in use. Indeed, previous work in our group based on these models have shown
      that propofol dosage required by children to induce general anesthesia is inversely
      proportional to the age, which could be explained by biases in these models, different
      sensitivity to propofol at different ages and sizes, etc.

      The effect of propofol in the brain is described by its pharmacodynamics, but in children
      this is still in debate. Using a brain activity monitor (BIS), the effect of propofol at the
      central nervous system can be analyzed under a model of nonlinear mixed effects (NONMEM) and
      establish the time to peak effect to characterize in detail the pharmacodynamics of this
      drug.

      Integrating pharmacokinetic and pharmacodynamic data, a pharmacokinetic/pharmacodynamic
      (PK/PD) model for the pediatric population can be derived.

      The aim of this paper is to describe the first PK / PD model of propofol in children, valid
      for different ages and to analyze them in the context of different body composition
      parameters.

      The importance of this study is that its results will publish the missing link in the
      pediatric pharmacology of propofol, which will encourage more research and more widespread
      use of this technique in the pediatric population.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Propofol plasmatic levels</measure>
    <time_frame>From start of infusion: 5 min, 15 min, 45 min; from bolus 0 min, 1 min, 3 min, 5 min, 10 min; after infusion 30 min, 60 min, 120 min, 360 min</time_frame>
    <description>Measured by high pressure liquid chromatography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemodynamics</measure>
    <time_frame>Entering operating room up to end of anesthesia</time_frame>
    <description>Heart rate and arterial pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Propofol total dose</measure>
    <time_frame>Start of propofol infusion until it ends</time_frame>
    <description>Measured in milligrams</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sevoflurane total dose</measure>
    <time_frame>Start of inhalational induction to zero end tidal concentration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse oximetry</measure>
    <time_frame>Entering operating room up to end of anesthesia</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BIS</measure>
    <time_frame>Entering operating room up to end of anesthesia</time_frame>
    <description>Depth of anesthesia will be recorded with BIS monitor</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Ages 1 year - 3 years 11 months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Propofol infusion, measuring of plasmatic levels of propofol through venous sampling</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ages 4 years - 8 years 11 months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Propofol infusion, measuring of plasmatic levels of propofol through venous sampling</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ages 9 years - 11 years 11 months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Propofol infusion, measuring of plasmatic levels of propofol through venous sampling</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Propofol infusion will be started after inhalational induction by manual infusion by the following scheme:
First 15 minutes: 15 mg/kg/min
16 to 30 minutes: 13 mg/kg/min
31 to 60 minutes: 11 mg/kg/min
61 to 120 minutes: 10 mg/kg/min Dose will be titrated to maintain BIS between 40 - 50.
Venous sampling for plasmatic levels of propofol measuring will be made at the following moments:
5, 15 and 25 minutes of starting infusion,
1, 3, 5, 7, 9 and 12 minutes of bolus and,
5, 25, 60 and 120 minutes of infusion ended.</description>
    <arm_group_label>Ages 1 year - 3 years 11 months</arm_group_label>
    <arm_group_label>Ages 4 years - 8 years 11 months</arm_group_label>
    <arm_group_label>Ages 9 years - 11 years 11 months</arm_group_label>
    <other_name>Diprivan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children aged 1 year through 11 years 11 months and 29 days old.

          -  American Society of Anesthesiology (ASA) score 1 or 2.

          -  Elective surgery of more than 1 hour of expected duration.

          -  Written informed consent signed by parents or legal guardians.

          -  Oral and written consent in children aged over 7 years old.

        Exclusion Criteria:

          -  Known allergies to study drugs.

          -  Use of any medication acting on central nervous system in the last 24 hours previous
             to surgery.

          -  Chronic cardiac, renal, hepatic or neurologic disease that determines abnormal
             function.

          -  Difficult airway (predicted or known).

          -  Use of neuraxial anesthesia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ricardo Fuentes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rose M Heider, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ricardo Fuentes, MD</last_name>
    <phone>56-9-77648344</phone>
    <email>rfuente@med.puc.cl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Division de Anestesia - Pontificia Universidad Catolica de Chile</name>
      <address>
        <city>Santiago</city>
        <state>Region Metropolitana</state>
        <zip>8330024</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernando R Altermatt, MSc</last_name>
      <phone>56-2-23543270</phone>
      <email>fernando.altermatt@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Hernan E Auad, MD</last_name>
      <phone>56-2-23543270</phone>
      <email>hernan_auad@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <reference>
    <citation>Gibert S, Sabourdin N, Louvet N, Moutard ML, Piat V, Guye ML, Rigouzzo A, Constant I. Epileptogenic effect of sevoflurane: determination of the minimal alveolar concentration of sevoflurane associated with major epileptoid signs in children. Anesthesiology. 2012 Dec;117(6):1253-61. doi: 10.1097/ALN.0b013e318273e272.</citation>
    <PMID>23103557</PMID>
  </reference>
  <reference>
    <citation>Kearns GL, Reed MD. Clinical pharmacokinetics in infants and children. A reappraisal. Clin Pharmacokinet. 1989;17 Suppl 1:29-67. Review.</citation>
    <PMID>2692939</PMID>
  </reference>
  <reference>
    <citation>Fuentes R, Cortínez I, Ibacache M, Concha M, Muñoz H. Propofol concentration to induce general anesthesia in children aged 3-11 years with the Kataria effect-site model. Paediatr Anaesth. 2015 Jun;25(6):554-9. doi: 10.1111/pan.12657. Epub 2015 Apr 16.</citation>
    <PMID>25880448</PMID>
  </reference>
  <reference>
    <citation>Rigouzzo A, Servin F, Constant I. Pharmacokinetic-pharmacodynamic modeling of propofol in children. Anesthesiology. 2010 Aug;113(2):343-52. doi: 10.1097/ALN.0b013e3181e4f4ca.</citation>
    <PMID>20613468</PMID>
  </reference>
  <reference>
    <citation>Coppens MJ, Eleveld DJ, Proost JH, Marks LA, Van Bocxlaer JF, Vereecke H, Absalom AR, Struys MM. An evaluation of using population pharmacokinetic models to estimate pharmacodynamic parameters for propofol and bispectral index in children. Anesthesiology. 2011 Jul;115(1):83-93. doi: 10.1097/ALN.0b013e31821a8d80.</citation>
    <PMID>21555936</PMID>
  </reference>
  <reference>
    <citation>Panchatsharam S, Callaghan M, Day R, Sury MR. Measured versus predicted blood propofol concentrations in children during scoliosis surgery. Anesth Analg. 2014 Nov;119(5):1150-7. doi: 10.1213/ANE.0000000000000413.</citation>
    <PMID>25225889</PMID>
  </reference>
  <reference>
    <citation>Howie SR. Blood sample volumes in child health research: review of safe limits. Bull World Health Organ. 2011 Jan 1;89(1):46-53. doi: 10.2471/BLT.10.080010. Epub 2010 Sep 10. Review.</citation>
    <PMID>21346890</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2015</study_first_submitted>
  <study_first_submitted_qc>September 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2015</study_first_posted>
  <last_update_submitted>October 10, 2016</last_update_submitted>
  <last_update_submitted_qc>October 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics, pharmacodynamics, propofol, pediatrics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

